Sign up to save your podcasts
Or
Share AI Access Brief Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
AI Access Brief Podcast
AI Access Brief Podcast episodes
- MHRA-NICE Pathway Under Fire, Clinical Trial Targets HitEpisode 13 — 27 May 2026LSE expert challenges the new UK aligned drug approval pathway as industry-favoring while EU reports progress on 2030 clinical trial targets. NICE approves first HER2-targeted therapy for bile duct cancer as regulatory reforms reshape the clinical research landscape.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast5 min
- Critical Medicines Act and NICE Technology PrioritiesEpisode 12 — 27 May 2026The EU Critical Medicines Act's provisional agreement introduces supply chain resilience metrics into HTA frameworks, while NICE advances systematic technology adoption and new prioritisation criteria. EMA maintains strong approval rates as European HTA bodies expand beyond traditional pharmacoeconomic assessments.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- CHMP Pipeline Surge, NICE Threshold Jump, JCA Device PushEpisode 11 — 27 May 2026EMA's CHMP recommended eight medicines including first-ever PROS treatment while NICE raised cost-effectiveness thresholds to £25,000-35,000 per QALY. The EU's Joint Clinical Assessment framework expands into medical devices with five assessments planned for June 2026.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- Oral GLP-1s, AI Dominance, and Digital Health ParityEpisode 10 — 27 May 2026EMA approves first oral GLP-1 for weight management while AI rises to top HEOR trend. NICE expands technology appraisals to digital health technologies and FDA raises real-world data standards.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- UK Alignment Acceleration and EU JCA ImplementationEpisode 9 — 27 May 2026Marcus and Sara examine the NICE-MHRA aligned pathway's potential to accelerate UK medicine access by six months and debate whether 50 EU joint clinical assessments starting this year represents genuine coordination or administrative overhead. They disagree on US drug pricing policy effectiveness and discuss expanding international HTA collaboration benefits.Hosted by Marcus and Sara.Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast6 min
- NICE Unified Prioritisation and EMA Regulatory MomentumEpisode 18 — 27 May 2026NICE transforms guidance selection with unified prioritisation framework and EQ-5D-5L implementation while EMA shows regulatory momentum with eight May approvals. The episode examines operational impacts on evidence strategy and market access planning.Hosted by Marcus and Sara.Outcomes Analytica Podcast — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast7 min
- NICE Threshold Shift, Critical Medicines Act, and MFN Reality CheckEpisode 8 — 26 May 2026NICE confirms new £25,000-£35,000/QALY thresholds while EU reaches provisional agreement on Critical Medicines Act. Trump administration's MFN pricing projects $529 billion savings despite continued industry price increases.Hosted by Marcus and Sara.Outcomes Analytica Podcast — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast4 min
- CHMP Momentum, Critical Medicines Act, HTA Capacity ScalingEpisode 17 — 26 May 2026EMA's CHMP delivered eight approvals including nerandomilast for pulmonary fibrosis while the Critical Medicines Act reached provisional political agreement. EU HTA capacity building expands with multilingual eLearning modules as joint clinical assessments scale to 35 oncology reviews despite persistent bottlenecks.Hosted by Marcus and Sara.Outcomes Analytica Podcast — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast5 min
- Critical Medicines Act Shapes EU HTA LandscapeEpisode 16 — 26 May 2026The EU's Critical Medicines Act provisional agreement combines regulatory tools with industrial policy to strengthen medicine supply resilience across 200+ active substances. HTACG scales joint clinical assessments while NICE operationalizes new thresholds amid evolving digital health technology frameworks.Hosted by Marcus and Sara.Outcomes Analytica Podcast — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast8 min
- HTACG Data Transparency and NICE Prioritisation OverhaulEpisode 15 — 25 May 2026HTACG publishes crucial data transparency principles distinguishing commercially confidential information for joint clinical assessments. NICE launches unified prioritisation framework with eight principles from public dialogue, while EMA approves challenging orphan medicines and EFPIA raises MFN pricing access concerns.Hosted by Marcus and Sara.Outcomes Analytica Podcast — Daily briefings on HEOR, HTA strategy and the evidence access landscape.Full transcript and sources at outcomes-analytica.no/podcast3 min
About AI Access Brief Podcast
From the publisher's feed
AI Generated Daily briefings on HEOR, HTA strategy and the evidence access landscape. For pharmaceutical and biotech professionals navigating regulatory-payer alignment, HTA submissions, and…
evidence strategy.